Skip to main content
IDWeek 2022 Main banner
Save the Date IDWeek 2023
IDWeek 2022 On Demand
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Watch the live stream on the conference website.
Watch the live stream on the conference website.

Pranita Tamma, MD, MHS

Associate Professor
Johns Hopkins School of Medicine
Baltimore, Maryland, United States

Dr. Tamma is an Associate Professor of Pediatrics and the Director of the Pediatric Antimicrobial Stewardship Program at The Johns Hopkins University School of Medicine. She is also an Associate Professor in the Department of Epidemiology at The Johns Hopkins Bloomberg School of Public Health. Her research focuses on: (a) elucidating the mechanisms of resistance in gram-negative organisms, (b) developing and enhancing rapid phenotypic and genotypic methods to identify gram-negative resistance to enable critically-ill patients to be placed on appropriate antibiotic therapy as early as possible, and (c) identifying optimal treatment strategies for patients infected with multidrug-resistant gram-negative infections, including leading a multicenter NIH-funded Phase 2 study of bacteriophage therapy. She has past and present funding from the NIH, FDA, CDC, and AHRQ to investigate these areas. She had the opportunity to work in the national and international arena to advance including: serving as an Editor at Antimicrobial Agents and Chemotherapy and The Journal of the Pediatric Infectious Diseases Society; serving as 1 of 12 international voting members of the Clinical Laboratory and Standards Institute that provides international guidance on phenotypic and genotypic methods for identifying antimicrobial resistance; serving as a voting member of the NIH-funded Antibacterial Resistance Leadership Group Gram-Negative Resistance Committee; and serving as the Co-Chair for the Infectious Diseases Society of America Antimicrobial Resistance Guidance.

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentation(s):